{"title":"[Diagnosis and treatment of epilepsy: from seizure control to targeted intervention].","authors":"X Wang","doi":"10.3760/cma.j.cn112137-20250514-01179","DOIUrl":null,"url":null,"abstract":"<p><p>Epilepsy management is experiencing a fundamental paradigm shift, moving beyond seizure control toward precision medicine. Despite continuous innovation in antiseizure medications, approximately one-third of patients still develop drug-resistant epilepsy, highlighting the limitations of traditional symptomatic treatment. In recent years, interdisciplinary convergence has catalyzed a series of breakthrough technologies: cerebral organoid technology demonstrates exceptional capability in modeling pathological features of genetic epilepsy, providing revolutionary tools for personalized drug screening and disease-modifying therapy; multimodal brain network imaging has revealed neural network characteristics of epilepsy, driving the transition of treatment models toward precise neural network-based interventions; the synergistic application of AI-driven drug target prediction, novel nano-drug delivery systems, and gene editing technologies offers innovative strategies for intervening in disease progression. Looking ahead, establishing standardized biomarker systems, conducting real-world studies, and optimizing clinical guidelines will further advance epilepsy treatment from seizure control to disease modification, bringing new therapeutic hope to patients.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 31","pages":"2611-2615"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua yi xue za zhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112137-20250514-01179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Epilepsy management is experiencing a fundamental paradigm shift, moving beyond seizure control toward precision medicine. Despite continuous innovation in antiseizure medications, approximately one-third of patients still develop drug-resistant epilepsy, highlighting the limitations of traditional symptomatic treatment. In recent years, interdisciplinary convergence has catalyzed a series of breakthrough technologies: cerebral organoid technology demonstrates exceptional capability in modeling pathological features of genetic epilepsy, providing revolutionary tools for personalized drug screening and disease-modifying therapy; multimodal brain network imaging has revealed neural network characteristics of epilepsy, driving the transition of treatment models toward precise neural network-based interventions; the synergistic application of AI-driven drug target prediction, novel nano-drug delivery systems, and gene editing technologies offers innovative strategies for intervening in disease progression. Looking ahead, establishing standardized biomarker systems, conducting real-world studies, and optimizing clinical guidelines will further advance epilepsy treatment from seizure control to disease modification, bringing new therapeutic hope to patients.